Global Rank
#42675
Country Rank
n/a
Market Cap
5.71 M
Price
1.02
Change (%)
0.29%
Volume
247
Genotech's latest marketcap:
5.71 M
As of 06/06/2025, Genotech's market capitalization has reached $5.71 M. According to our data, Genotech is the 42675th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 5.71 M |
| Revenue (ttm) | 0 |
| Net Income (ttm) | 0 |
| Shares Out | 5.6 M |
| EPS (ttm) | 0 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | n/a |
Market Cap Chart
Data Updated: 06/06/2025
Genotech's yearly market capitalization.
Genotech has seen its market value drop from ₩19.85 B to ₩7.82 B since 2020, representing a total decrease of 60.59% and an annual compound decline rate (CAGR) of 18.94%.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/06/2025 | ₩7.82 B | 7.63% |
| 12/30/2024 | ₩7.27 B | -31.58% |
| 12/28/2023 | ₩10.62 B | -34.36% |
| 12/29/2022 | ₩16.18 B | -23.65% |
| 12/30/2021 | ₩21.19 B | 6.77% |
| 12/30/2020 | ₩19.85 B |
Company Profile
About Genotech Corporation
Genotech Corporation is a biotechnology company specializing in gene synthesis, genome analysis, and biopharmaceutical solutions. Headquartered in Daejeon, South Korea, the company serves clients both domestically and internationally.
Products & Services
- Oligonucleotides: Standard, modified, dual-labeled, and synthesis oligonucleotides.
- Gene Synthesis: Custom gene synthesis services.
- DNA Sequencing:
- Sanger DNA sequencing (standard DNA, 16S/ITS, insert clone sequencing, primer walking).
- Next-generation sequencing (NGS).
- Bioinformatics & Genomics: SNP discovery/analysis, sequence finishing, and bioinformatics services.
- Molecular Diagnostics: Diagnostic kits for research and clinical applications.
- Active Pharmaceutical Ingredients (APIs): Vancomycin HCI, teicoplanin, and tacrolimus.
Research & Development
Genotech Corporation focuses on biopharmaceutical innovation, including:
- Development of incrementally modified drugs.
- Discovery of new molecular entities using functional genomics and metabolic reconstruction technologies.
Founded: 1997
Headquarters: Daejeon, South Korea
Frequently Asked Questions
-
What is Genotech's (XKON-066830) current market cap?As of 06/06/2025, Genotech (including the parent company, if applicable) has an estimated market capitalization of $5.71 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Genotech (XKON-066830) rank globally by market cap?Genotech global market capitalization ranking is approximately 42675 as of 06/06/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.